Top

Published in:

01-08-2019 | Prostate Cancer | Original Article

Immunohistochemical expression of mismatch repair proteins (MSH2, MSH6, MLH1, and PMS2) in prostate cancer: correlation with grade groups (WHO 2016) and ERG and PTEN status

Authors: Raquel Albero-González, Silvia Hernández-Llodrà, Nuria Juanpere, Marta Lorenzo, Adrià Lloret, Laura Segalés, Xavier Duran, Lluís Fumadó, Lluís Cecchini, Josep Lloreta-Trull

Published in: Virchows Archiv | Issue 2/2019

Abstract

The role of DNA MMR genes in prostate cancer (PrCa) is controversial, as genetic alterations leading to microsatellite instability are incompletely defined in these tumors. ERG rearrangements and PTEN loss are concomitant events in PrCa. The aim of this study has been to analyze the immunohistochemical (IHC) expression of MSH2, MSH6, MLH1, PMS2, ERG, and PTEN and their potential association with the grade group (GG) grading system (WHO 2016) and PSA recurrence in a series of 200 PrCa (PSMAR-Biobank, Barcelona, Spain). MSH2, MLH1, PMS2, and PTEN losses were documented in 8%, 5%, 2%, and 36.5%, respectively. ERG expression was found in 48%. MSH6 showed an increase of expression with respect to basal levels in 42.1% of the cases. A statistical association between MSH6 overexpression and GG5 was found (p = 0.0281). ERG-wild-type cases were associated with single MSH2 loss (p = 0.024), and MSH2 and/or MLH1 loss (p = 0.019). The percentage of cases with PTEN loss was 20.5% (8/39) in GG1, 37.6% (53/141) of clustered GG2 to 4, and 60% (12/20) of GG5 (chi-square test, p = 0.01). Thus, PTEN expression loss was statistically more frequent in the upper-grade tumors. PMS2 loss was an infrequent event, but it was statistically associated with shorter time to PSA recurrence (p = 0.011). These results suggest the existence of an alternative non-ERG pathway associated with MSH2 or MLH1 expression loss. MSH6 overexpression could be a marker of aggressiveness in PrCa. The IHC assessment of DNA MMR proteins, ERG and PTEN, could identify different altered PrCa pathways, which could aid patient stratification.

Li GM (2008) Mechanisms and functions of DNA mismatch repair. Cell Res 18(1):85–98CrossRefPubMed

Kolodner RD, Marsischky GT (1999) Eukaryotic DNA mismatch repair. Curr Opin Genet Dev 9(1):89–96CrossRefPubMed

Liu J, Hanne J, Britton BM, Kim D, Lee JB, Fishel R (2016) Cascading MutS and MutL sliding clamps control DNA diffusion to activate mismatch repair. Nature 539(7630):583–587CrossRefPubMedPubMedCentral

Wood RD, Mitchell M, Sgouros J, Lindahl T (2001) Human DNA repair genes. Science 291(5507):1284–1289CrossRefPubMed

Pritchard CC, Morrissey C, Kumar A, Zhang X, Smith C, Coleman I, Salipante SJ, Milbank J, Yu M, Grady WM, Tait JF, Corey E, Vessella RL, Walsh T, Shendure J, Nelson PS (2014) Complex MSH2 and MSH6 mutations in hypermutated microsatellite unstable advanced prostate cancer. Nat Commun 5:4988CrossRefPubMed

Cancer Genome Atlas Network (2012) Comprehensive molecular characterization of human colon and rectal cancer. Nature 487(7407):330–337CrossRef

Cancer Genome Atlas Network, Kandoth C, Schultz N, Cherniack AD, Akbani R, Liu Y, Shen H, Robertson AG, Pashtan I, Shen R, Benz CC, Yau C, Laird PW, Ding L, Zhang W, Mills GB, Kucherlapati R, Mardis ER, Levine DA (2013) Integrated genomic characterization of endometrial carcinoma. Nature 497(7447):67–73CrossRef

Beltran H (2013) DNA mismatch repair in prostate cancer. J Clin Oncol 31(14):1782–1784CrossRefPubMed

Guedes LB, Antonarakis ES, Schweizer MT, Mirkheshti N, Almutairi F, Park JC, Glavaris S, Hicks J, Eisenberger MA, De Marzo AM, Epstein JI, Isaacs WB, Eshleman JR, Pritchard CC, Lotan TL (2017) MSH2 loss in primary prostate cancer. Clin Cancer Res 23(22):6863–6874CrossRefPubMedPubMedCentral

10.

Chen Y, Wang J, Fraig MM, Metcalf J, Turner WR, Bissada NK, Watson DK, Schweinfest CW (2001) Defects of DNA mismatch repair in human prostate cancer. Cancer Res 61(10):4112–4121PubMed

11.

Norris AM, Woodruff RD, D'Agostino RB Jr, Clodfelter JE, Scarpinato KD (2007) Elevated levels of the mismatch repair protein PMS2 are associated with prostate cancer. Prostate 67(2):214–225CrossRefPubMed

12.

Burger M, Denzinger S, Hammerschmied CG, Tannapfel A, Obermann EC, Wieland WF, Hartmann A, Stoehr R (2006) Elevated microsatellite alterations at selected tetranucleotides (EMAST) and mismatch repair gene expression in prostate cancer. J Mol Med 84(10):833–841CrossRefPubMed

13.

Norris AM, Gentry M, Peehl DM, D'Agostino R Jr, Scarpinato KD (2009) The elevated expression of a mismatch repair protein is a predictor for biochemical recurrence after radical prostatectomy. Cancer Epidemiol Biomark Prev 18(1):57–64CrossRef

14.

Wilczak W, Rashed S, Hube-Magg C, Kluth M, Simon R, Büscheck F, Clauditz TS, Grupp K, Minner S, Tsourlakis MC, Möller-Koop C, Graefen M, Adam M, Haese A, Wittmer C, Sauter G, Izbicki JR, Huland H, Schlomm T, Steurer S, Krech T, Lebok P (2017) Up-regulation of mismatch repair genes MSH6, PMS2 and MLH1 parallels development of genetic instability and is linked to tumor aggressiveness and early PSA recurrence in prostate cancer. Carcinogenesis 38(1):19–27CrossRefPubMed

15.

Velasco A, Albert PS, Rosenberg H, Martinez C, Leach FS (2002) Clinicopathologic implications of hMSH2 gene expression and microsatellite instability in prostate cancer. Cancer Biol Ther 1(4):362–367PubMed

16.

Langeberg WJ, Kwon EM, Koopmeiners JS, Ostrander EA, Stanford JL (2010) Population-based study of the association of variants in mismatch repair genes with prostate cancer risk and outcomes. Cancer Epidemiol Biomarkers Prev 19(1):258–264CrossRefPubMedPubMedCentral

17.

Berger MF, Lawrence MS, Demichelis F, Drier Y, Cibulskis K, Sivachenko AY, Sboner A, Esgueva R, Pflueger D, Sougnez C, Onofrio R, Carter SL, Park K, Habegger L, Ambrogio L, Fennell T, Parkin M, Saksena G, Voet D, Ramos AH, Pugh TJ, Wilkinson J, Fisher S, Winckler W, Mahan S, Ardlie K, Baldwin J, Simons JW, Kitabayashi N, MacDonald TY, Kantoff PW, Chin L, Gabriel SB, Gerstein MB, Golub TR, Meyerson M, Tewari A, Lander ES, Getz G, Rubin MA, Garraway LA (2011) The genomic complexity of primary human prostate cancer. Nature 470(7333):214–220CrossRefPubMedPubMedCentral

18.

Tomlins SA, Bjartell A, Chinnaiyan AM, Jenster G, Nam RK, Rubin MA, Schalken JA (2009) ETS gene fusions in prostate cancer: from discovery to daily clinical practice. Eur Urol 56(2):275–286CrossRefPubMed

19.

Cancer Genome Atlas Research Network (2015) The molecular taxonomy of primary prostate cancer. Cell 163(4):1011–1025CrossRef

20.

Lotan TL, Gurel B, Sutcliffe S, Esopi D, Liu W, Xu J, Hicks JL, Park BH, Humphreys E, Partin AW, Han M, Netto GJ, Isaacs WB, De Marzo AM (2011) PTEN protein loss by immunostaining: analytic validation and prognostic indicator for a high risk surgical cohort of prostate cancer patients. Clin Cancer Res 17(20):6563–6573CrossRefPubMedPubMedCentral

21.

Yoshimoto M, Ding K, Sweet JM, Ludkovski O, Trottier G, Song KS, Joshua AM, Fleshner NE, Squire JA, Evans AJ (2013) PTEN losses exhibit heterogeneity in multifocal prostatic adenocarcinoma and are associated with higher Gleason grade. Mod Pathol 26(3):435–447CrossRefPubMed

22.

Hernández S, Font-Tello A, Juanpere N, de Muga S, Lorenzo M, Salido M, Fumadó L, Serrano L, Cecchini L, Serrano S, Lloreta J (2016) Concurrent TMPRSS2-ERG and SLC45A3-ERG rearrangements plus PTEN loss are not found in low grade prostate cancer and define an aggressive tumor subset. Prostate 76(9):854–865CrossRefPubMed

23.

Han B, Mehra R, Lonigro RJ, Wang L, Suleman K, Menon A, Palanisamy N, Tomlins SA, Chinnaiyan AM, Shah RB (2009) Fluorescence in situ hybridization study shows association of PTEN deletion with ERG rearrangement during prostate cancer progression. Mod Pathol 22(8):1083–1093CrossRefPubMedPubMedCentral

24.

King JC, Xu J, Wongvipat J, Hieronymus H, Carver BS, Leung DH, Taylor BS, Sander C, Cardiff RD, Couto SS, Gerald WL, Sawyers CL (2009) Cooperativity of TMPRSS2-ERG with PI3-kinase pathway activation in prostate oncogenesis. Nat Genet 41(5):524–526CrossRefPubMedPubMedCentral

25.

Carver BS, Tran J, Gopalan A, Chen Z, Shaikh S, Carracedo A, Alimonti A, Nardella C, Varmeh S, Scardino PT, Cordon-Cardo C, Gerald W, Pandolfi PP (2009) Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate. Nat Genet 41(5):619–624CrossRefPubMedPubMedCentral

26.

Krohn A, Freudenthaler F, Harasimowicz S, Kluth M, Fuchs S, Burkhardt L, Stahl P, Tsourlakis MC, Bauer M, Tennstedt P, Graefen M, Steurer S, Sirma H, Sauter G, Schlomm T, Simon R, Minner S (2014) Heterogeneity and chronology of PTEN deletion and ERG fusion in prostate cancer. Mod Pathol 27(12):1612–1620CrossRefPubMed

27.

Grasso CS, Wu YM, Robinson DR, Cao X, Dhanasekaran SM, Khan AP, Quist MJ, Jing X, Lonigro RJ, Brenner JC, Asangani IA, Ateeq B, Chun SY, Siddiqui J, Sam L, Anstett M, Mehra R, Prensner JR, Palanisamy N, Ryslik GA, Vandin F, Raphael BJ, Kunju LP, Rhodes DR, Pienta KJ, Chinnaiyan AM, Tomlins SA (2012) The mutational landscape of lethal castration-resistant prostate cancer. Nature 487(7406):239–243CrossRefPubMedPubMedCentral

28.

Taylor BS, Schultz N, Hieronymus H, Gopalan A, Xiao Y, Carver BS, Arora VK, Kaushik P, Cerami E, Reva B, Antipin Y, Mitsiades N, Landers T, Dolgalev I, Major JE, Wilson M, Socci ND, Lash AE, Heguy A, Eastham JA, Scher HI, Reuter VE, Scardino PT, Sander C, Sawyers CL, Gerald WL (2010) Integrative genomic profiling of human prostate cancer. Cancer Cell 18(1):11–22CrossRefPubMedPubMedCentral

29.

FDA grants accelerated approval to pembrolizumab for first tissue/site agnostic indication [U.S. Food and Drug Administration web site]. May 23, 2017. Available at: https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm560040.htm. Accessed 7 Oct 2018

30.

Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, Skora AD, Luber BS, Azad NS, Laheru D, Biedrzycki B, Donehower RC, Zaheer A, Fisher GA, Crocenzi TS, Lee JJ, Duffy SM, Goldberg RM, de la Chapelle A, Koshiji M, Bhaijee F, Huebner T, Hruban RH, Wood LD, Cuka N, Pardoll DM, Papadopoulos N, Kinzler KW, Zhou S, Cornish TC, Taube JM, Anders RA, Eshleman JR, Vogelstein B, Diaz LA Jr (2015) PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med 372(26):2509–2520CrossRefPubMedPubMedCentral

31.

Lord CJ, Ashworth A (2012) The DNA damage response and cancer therapy. Nature 481(7381):287–294CrossRefPubMed

32.

Epstein JI, Zelefsky MJ, Sjoberg DD, Nelson JB, Egevad L, Magi-Galluzzi C, Vickers AJ, Parwani AV, Reuter VE, Fine SW, Eastham JA, Wiklund P, Han M, Reddy CA, Ciezki JP, Nyberg T, Klein EA (2016) A contemporary prostate cancer grading system: a validated alternative to the Gleason score. Eur Urol 69(3):428–435CrossRefPubMed

33.

Hernández-Llodrà S, Juanpere N, de Muga S, Lorenzo M, Gil J, Font-Tello A, Agell L, Albero-González R, Segalés L, Merino J, Serrano L, Fumadó L, Cecchini L, Lloreta-Trull J (2017) ERG overexpression plus SLC45A3 (prostein) and PTEN expression loss: strong association of the triple hit phenotype with an aggressive pathway of prostate cancer progression. Oncotarget 8(43):74106–74118CrossRefPubMedPubMedCentral

34.

Shia J, Klimstra DS, Nafa K, Offit K, Guillem JG, Markowitz AJ, Gerald WL, Ellis NA (2005) Value of immunohistochemical detection of DNA mismatch repair proteins in predicting germline mutation in hereditary colorectal neoplasms. Am J Surg Pathol 29(1):96–104CrossRefPubMed

35.

Basu S, Majumder S, Bhowal A, Ghosh A, Naskar S, Nandy S, Mukherjee S, Sinha RK, Basu K, Karmakar D, Banerjee S, Sengupta S (2015) A study of molecular signals deregulating mismatch repair genes in prostate cancer compared to benign prostatic hyperplasia. PLoS One 10(5):e0125560CrossRefPubMedPubMedCentral

36.

Li M, Zhang Q, Liu L, Lu W, Wei H, Li RW, Lu S (2013) Expression of the mismatch repair gene hMLH1 is enhanced in non-small cell lung cancer with EGFR mutations. PLoS One 8(10):e78500CrossRefPubMedPubMedCentral

37.

Li M, Liu L, Wang Z, Wang L, Liu Z, Xu G, Lu S (2008) Overexpression of hMSH2 and hMLH1 protein in certain gastric cancers and their surrounding mucosae. Oncol Rep 19(2):401–406PubMed

38.

Srivastava T, Chattopadhyay P, Mahapatra AK, Sarkar C, Sinha S (2004) Increased hMSH2 protein expression in glioblastoma multiforme. J Neuro-Oncol 66(1–2):51–57CrossRef

39.

Velasco A, Hewitt SM, Albert PS, Hossein M, Rosenberg H, Martinez C, Sagalowsky AI, McConnell JD, Marston W, Leach FS (2002) Differential expression of the mismatch repair gene hMSH2 in malignant prostate tissue is associated with cancer recurrence. Cancer 94(3):690–699. Erratum in: Cancer 94(10):2800CrossRefPubMed

40.

Tomlins SA, Rhodes DR, Perner S, Dhanasekaran SM, Mehra R, Sun XW, Varambally S, Cao X, Tchinda J, Kuefer R, Lee C, Montie JE, Shah RB, Pienta KJ, Rubin MA, Chinnaiyan AM (2005) Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 310(5748):644–648CrossRefPubMed

41.

Clark JP, Cooper CS (2009) ETS gene fusions in prostate cancer. Nat Rev Urol 6:429–439CrossRefPubMed

42.

Esgueva R, Perner S, LaFargue C J, Scheble V, Stephan C, Lein M, Fritzsche FR, Dietel M, Kristiansen G, Rubin MA (2010) Prevalence of TMPRSS2-ERG and SLC45A3-ERG gene fusions in a large prostatectomy cohort. Mod Pathol 23:539–546CrossRefPubMedPubMedCentral

43.

Font-Tello A, Juanpere N, De Muga S, Lorenzo M, Lorente JA, Fumado L, Serrano L, Serrano S, Lloreta J, Hernández S (2015) Association of ERG and TMPRSS2-ERG with grade, stage, and prognosis of prostate cancer is dependent on their expression levels. Prostate 75(11):1216–1226CrossRefPubMed

44.

Gumuskaya B, Gurel B, Fedor H, Tan HL, Weier CA, Hicks JL, Haffner MC, Lotan TL, De Marzo AM (2013) Assessing the order of critical alterations in prostate cancer development and progression by IHC: further evidence that PTEN loss occurs subsequent to ERG gene fusion. Prostate Cancer Prostatic Dis 16(2):209–215CrossRefPubMedPubMedCentral

Title: Immunohistochemical expression of mismatch repair proteins (MSH2, MSH6, MLH1, and PMS2) in prostate cancer: correlation with grade groups (WHO 2016) and ERG and PTEN status
Authors: Raquel Albero-González
Silvia Hernández-Llodrà
Nuria Juanpere
Marta Lorenzo
Adrià Lloret
Laura Segalés
Xavier Duran
Lluís Fumadó
Lluís Cecchini
Josep Lloreta-Trull
Publication date: 01-08-2019
Publisher: Springer Berlin Heidelberg
Keywords: Prostate Cancer
Prostate Cancer
Published in: Virchows Archiv / Issue 2/2019
Print ISSN: 0945-6317
Electronic ISSN: 1432-2307
DOI: https://doi.org/10.1007/s00428-019-02591-z

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Immunohistochemical expression of mismatch repair proteins (MSH2, MSH6, MLH1, and PMS2) in prostate cancer: correlation with grade groups (WHO 2016) and ERG and PTEN status

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2019

Emerging relationships between papillary proliferation of the endometrium and endometrial carcinoma: evidence from an immunohistochemical and molecular analysis

Differences in intra-tumoral macrophage infiltration and radiotherapy response among intrinsic subtypes in pT1-T2 breast cancers treated with breast-conserving surgery

Synoptic reporting increases quality of upper gastrointestinal cancer pathology reports

Challenging the prognostic impact of the new WHO and TNM classifications with special emphasis on HPV status in penile carcinoma

Machine learning approaches for pathologic diagnosis

Sinusoidal and pericellular fibrosis in adult post-transplant liver biopsies: association with hepatic stellate cell activation and patient outcome